Stock Under $10 with 50-100% upside potential - 14 Days FREE!

AVEO Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript

Stock quotes in this article: AVEO 

AVEO Pharmaceuticals (AVEO)

Q2 2012 Earnings Call

August 02, 2012 10:00 am ET

Executives

Monique Allaire

Tuan Ha-Ngoc - Chief Executive Officer, President and Director

William J. Slichenmyer - Chief Medical Officer

David B. Johnston - Chief Financial Officer and Principal Accounting Officer

Michael P. Bailey - Chief Commercial Officer

Analysts

John S. Sonnier - William Blair & Company L.L.C., Research Division

Adnan S. Butt - RBC Capital Markets, LLC, Research Division

Anupam Rama - JP Morgan Chase & Co, Research Division

Marshall Urist - Morgan Stanley, Research Division

Thomas Wei - Jefferies & Company, Inc., Research Division

Salveen J. Richter - Canaccord Genuity, Research Division

Howard Liang - Leerink Swann LLC, Research Division

Presentation

Operator

Good day, ladies and gentlemen, and welcome to the AVEO Oncology Second Quarter 2012 Financial Results Conference Call. My name is Derek, and I'll be your operator for today. [Operator Instructions] As a reminder, this conference is the recorded for replay purposes. I would now like to turn the conference over to Ms. Monique Allaire, Director of Investor Relations. Please proceed.

Monique Allaire

Thank you, Derek, and good morning, everyone. Today, we'll be talking about our second quarter 2012 financial results and key recent developments and achievements. With me are Tuan Ha-Ngoc, our President and Chief Executive Officer; Bill Slichenmyer, our Chief Medical Officer; and David Johnston, our Chief Financial Officer. In addition, joining us for the Q&A session will be Michael Bailey, our Chief Commercial Officer; and Elan Ezickson, our Executive Vice President and Chief Operating Officer.

The press release issued earlier today detailing our results is available on our website at aveooncology.com.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
TRY IT FREE

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Dividend Stock Advisor
TRY IT FREE
New! $49.95/yr

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Real Money
TRY IT FREE

24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.

Product Features:
  • Jim Cramer + 20 Wall Street pros
  • Intraday commentary & news
  • Real-time trading forum
  • Actionable trade ideas
Real Money Pro
TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass + 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 15,270.04 -37.13 -0.24%
NASDAQ 3,451.28 -12.02 -0.35%
S&P 500 1,646.52 -8.83 -0.53%
US 10 Yr 2.021% -0.005

Brokerage Partners

Advertising Partners
Special Features

Free Newsletters from TheStreet

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy. Manage Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs